분자유전학실험실 (단국대학교 분자생물학과)



 이성욱 ( 2010-05-06 13:26:07 , Hit : 2699
 Engineering Better Immune Cells

Scientists use synthetic biology to create drug-controlled T cells.

Engineering a molecular control switch into immune cells could improve their therapeutic potential. Scientists from Caltech have shown that putting an RNA-based toggle mechanism into both live mice and human T cells allows them to turn cell growth on and off with a specific drug. The researchers ultimately hope to implement the technology in T cell therapeutics, which are currently in clinical testing for treating cancer and other diseases.

"This system gives us the ability to control the fate and function of cell-based therapies," says Michael Jensen, director of the pediatric cancer program at the City of Hope, a research and treatment center in Duarte, CA, and an author of the paper.

Scientists have long hoped to harness the power of the immune system to kill cancer cells, which can evade immune detection. One approach is to isolate T cells--a type of white blood cell that helps tailor the body's response to specific pathogens--from a patient's blood, multiply them, and then inject them back into the patient. Thanks to advances in genetic engineering and gene therapy, researchers are now modifying the isolated cells to better attack cancer. For example, a number of therapies now being tested in patients use T cells engineered to carry a molecule that allows them to selectively bind to cancer cells.

These treatments have shown some success. One problem, however, is that unlike natural T cells, the engineered versions fail to multiply and don't persist in the bloodstream for long. That limits the cells' ability to recruit other parts of the immune system to kill the cancer. Giving patients an immune booster called interleukin 2 increases T cell survival and proliferation. However, the treatment is tough on patients--it requires chemotherapy and radiation to wipe out the natural T cells, enhancing the interaction between immune molecules and the modified cells.

"It does address one of the problems with T cell therapies, which is survival and persistence of these cells," says Darrel Irvine, a bioengineer at MIT who was not involved in the research. Irvine points out that one concern in enhancing T cells' growth is the possibility that growth could spin out of control. "But they have an elegant solution," he says. "Through this drug, they can turn it off."

Because the switch is made from RNA rather than proteins, it may also avoid another issue with existing modified T cells--triggering an attack from the immune system. "An important feature of their system is that it should not trigger a T cell response against the cells themselves," says Carl June, a pathologist at the University of Pennsylvania.

In addition to its implications for cancer treatment, the research is a significant step forward for synthetic biology. Most synthetic biology parts are created and tested in microbes, such as the research workhorses yeast and E. coli. But the new study showed this particular part can work in human cells as well.

Another of the switch's benefits is its modular design. Scientists can swap in different sensor and actuator components, so that different drugs can be used to trigger production of other immune molecules."We want to make them respond to inert molecules like vitamins, which are inexpensive and easy to use and nontoxic for the patient," says Jensen.

Smolke's team is now working on altering the system to work with other FDA-approved drugs, and engineering the switch into T cells with tumor recognition systems. Smolke says clinical testing of the technology is still a ways off--they need to show that the system is safe in animals, and that it can slow tumor growth in animal models of cancer.







1107   Dynamic view of the MS genome  이성욱 2010/05/01 2717
1106   Early-Earth cells modeled to show how first life forms might have packaged RNA  이성욱 2012/10/16 2515
1105   Editas Expands CRISPR Capabilities through New Technology Licensing  이성욱 2016/12/22 820
1104   Efficient Process Using microRNA Converts Human Skin Cells Into Neurons  이성욱 2011/07/19 2238
1103   Electronics Giant Samsung Makes First Big Biotech Play  이성욱 2013/02/22 3165
1102   EMA panel recommends approval of DAA regimen for patients with HCV  이성욱 2014/11/26 1282
1101   Embryonic stem cells improve vision for two women  이성욱 2012/01/25 2336
1100   Engineered Human Liver Tissue Grows in Mice  이성욱 2017/07/25 780
1099   Engineered Viruses Selectively Kill Cancer Cells  이성욱 2011/09/02 2444
  Engineering Better Immune Cells  이성욱 2010/05/06 2699
1097   EU, 2번째 유전자치료제 ‘스트림벨리스’ 승인  이성욱 2016/09/05 1146
1096   European regulators back first gene therapy drug  이성욱 2012/07/24 2669
1095   Exosomes Linked to Cancer Spread from Chemoresistant Tumors in Mice  이성욱 2019/01/15 778
1094   Expanding the reach of gene editing with a new CRISPR enzyme  이성욱 2018/10/26 399
1093   Experimental Hepatitis C Drug Shows Promise for Preventing Recurrence in Liver Transplant Patients  이성욱 2013/11/06 2134
1092   Experts find rogue stem cells in liver cancer  이성욱 2011/07/09 2570
1091   Fathers Can Pass Mitochondrial DNA to Children  이성욱 2018/12/26 793
1090   FDA approves 9-valent HPV vaccine for certain cancers  이성욱 2014/12/12 1142
1089   FDA Approves First Gene Therapy for Inherited Disease  이성욱 2017/12/22 512
1088   FDA Approves Gilead CAR-T Therapy Yescarta, Plans Regenerative Medicine Policy 'Soon'  이성욱 2017/10/20 608

[1][2][3][4][5][6][7][8] 9 [10]..[64] [다음 10개]
 

Copyright 1999-2021 Zeroboard / skin by ROBIN